Calidi Biotherapeutics shares are trading higher after the company announced collaboration with SIGA Technologies to advance Calidi's RTNova virotherapy for lung cancer and metastatic solid tumors.
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics shares are trading higher following the announcement of a collaboration with SIGA Technologies to advance Calidi's RTNova virotherapy for lung cancer and metastatic solid tumors.
June 10, 2024 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calidi Biotherapeutics shares are trading higher after announcing a collaboration with SIGA Technologies to advance its RTNova virotherapy for lung cancer and metastatic solid tumors.
The collaboration with SIGA Technologies is a significant development for Calidi Biotherapeutics, as it could enhance the company's virotherapy offerings and potentially lead to successful treatments for lung cancer and metastatic solid tumors. This positive news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
SIGA Technologies is collaborating with Calidi Biotherapeutics to advance Calidi's RTNova virotherapy for lung cancer and metastatic solid tumors.
The partnership with Calidi Biotherapeutics to advance RTNova virotherapy is a positive development for SIGA Technologies. This collaboration could enhance SIGA's portfolio and open new opportunities in the oncology market, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80